期刊文献+

醋酸钙联合西那卡塞治疗血液透析继发性甲状旁腺功能亢进的临床效果

在线阅读 下载PDF
导出
摘要 目的观察醋酸钙联合西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进(SHPT)的临床效果。方法选取2018年6月—2020年6月于梧州市工人医院规律血液透析的SHPT患者60例,依照随机数字表法分为观察组和对照组,各30例。对照组予盐酸西那卡塞片治疗,观察组在对照组基础上加用醋酸钙片治疗,2组均持续治疗3个月。比较2组患者治疗效果,治疗前后甲状旁腺体积变化、相关生化指标[全段甲状旁腺激素(iPTH)、血钙、血磷、碱性磷酸酶(AKP)]差异及不良反应。结果2组治疗总有效率(76.67%vs.63.33%)比较差异无统计学意义(χ^(2)=1.270,P=0.260);治疗3个月后,观察组与对照组的甲状旁腺体积均明显缩小(P<0.01),但2组比较差异无统计学意义(P>0.05);2组iPTH、血磷、AKP水平均较治疗前下降(P<0.05或P<0.01),观察组血钙水平较治疗前升高(P<0.05),且观察组治疗后血钙水平高于对照组、血磷水平低于对照组(P均<0.01);观察组不良反应总发生率为6.67%,低于对照组的26.67%(χ^(2)=4.320,P=0.038)。结论醋酸钙联合西那卡塞治疗血液透析SHPT的临床效果肯定,能够有效稳定患者血钙水平,降低血磷,同时还能够预防低血钙症、高磷血症发生,安全性高,值得临床推广应用。
出处 《临床合理用药杂志》 2022年第11期105-107,共3页 Chinese Journal of Clinical Rational Drug Use
基金 梧州市科学研究与技术开发计划项目(201702036)。
  • 相关文献

参考文献6

二级参考文献77

  • 1Sbobeiri N, Adams MA, Holden RM. Phosphate: an old bone molecule but new cardiovascular risk factor[J]. Br J Clin Pharmacol, 2014,77 ( 1 ) : 39-54.
  • 2Marks J, Debnam ES, Unwin RJ. The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease[J]. Curr Opin Nephrol Hypertens,2013, 22(4) : 481-487.
  • 3Waheed AA, Pedraza F, Lenz O, et al. Phosphate control in end-stage renal disease: barriers and opportunities[J]. Nephrol Dial Transplant,2013,28(12) :2961-2968.
  • 4Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis [J]. JAMA,2011,305(11): 1119-1127.
  • 5Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild to-moderate kidney dysfunction [J]. Clin J Am Soc Nephrol, 2011,6(4) :883-891.
  • 6Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population[J]. Nephrol Dial Transplant, 2011, 26 (6): 1948- 1955.
  • 7Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients[J]. Nephrol Dial Transplant, 2007,22(10) :2909-2916.
  • 8Chue CD, Edwards NC, Davis LJ, et al. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease[J]. Nephrol Dial Transplant, 2011,26 (8): 2576-2582.
  • 9Sekiguchi S, Suzuki A, Asano S, et al. Phosphate overload induces podocyte injury via type III Na-dependent phosphate transporter[J]. Am J Physiol Renal Physiol, 2011,300 (4) :F848-856.
  • 10Shroff R. Phosphate is a vascular toxin[J]. Pediatr Nephrol, 2013,28(4) :583-593.

共引文献155

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部